Evaxion and EIB Finalize Strategic Agreement
Evaxion A/S has exciting news to share. The company has recently made significant strides in its financial management by finalizing a strategic agreement with the European Investment Bank (EIB). This agreement involves the conversion of a portion of their debt—€3.5 million—from a €7 million loan into equity. The favorable terms of this deal are aimed at enhancing Evaxion's position in the market.
Impact of the Equity Purchase
Under the terms of this agreement, EIB will acquire ordinary Evaxion warrants priced at $4.87. This purchase price reflects a substantial premium—89% above the company's share price as recorded at market close the previous day. This injection of equity means that, at a stroke, Evaxion’s financial landscape improves by approximately $4.1 million (€3.5 million). This is a substantial boost that underscores the company's resilience and potential for growth.
Streamlining Finances
The impact of this agreement goes beyond mere numbers. The significant reduction in overall liabilities is a step towards streamlining Evaxion's balance sheet. The company is poised for enhanced financial flexibility, which can lead to improved cash flow. These changes are crucial for a clinical-stage TechBio company like Evaxion, as they navigate the complexities of medical research and the progression of their innovative products.
Quote from CFO Thomas F. Schmidt
Expressing enthusiasm about the agreement, Thomas F. Schmidt, CFO of Evaxion, stated, "We are delighted to finalize the agreement with the EIB on favorable terms for Evaxion and our shareholders. The simplification of our balance sheet and enhanced cash flow are of paramount importance in managing our financial health moving forward." This sentiment echoes the company's commitment to creating long-term value for its stakeholders.
About Evaxion’s Vision and Technology
Evaxion is not just focused on its financial maneuvers; it is dedicated to pioneering advancements in the healthcare sector. Specializing in AI-powered vaccines through its unique platform known as AI-Immunology™, Evaxion aims to revolutionize how the human immune system is understood. The company has developed several promising treatments that address significant medical needs, particularly in oncology and infectious diseases.
Transforming Patient Care
This innovative approach not only aims to provide cutting-edge therapies but also underscores Evaxion's commitment to improving patient outcomes. With a continuous drive for research and development, Evaxion is at the forefront of creating personalized vaccine solutions that leverage the power of artificial intelligence.
Contact Information for Investors
Investors and interested stakeholders can reach out to Evaxion for more details. Mads Kronborg, Vice President of Investor Relations & Communication, is available at +45 53 54 82 96 for any inquiries. Additionally, those interested in further information can contact the company through their corporate email. While direct links were previously included, contacting Evaxion directly allows for tailored responses to investor questions.
Frequently Asked Questions
What is the significance of the EIB agreement for Evaxion?
The EIB agreement helps Evaxion convert part of its loan into equity, enhancing its financial stability and reducing liabilities.
How much equity does Evaxion gain from this agreement?
Evaxion gains approximately $4.1 million (€3.5 million) in equity from the agreement with the EIB.
Who is the CFO of Evaxion?
Thomas F. Schmidt serves as the CFO of Evaxion and plays a crucial role in strategic financial decision-making.
What technology does Evaxion develop?
Evaxion develops AI-powered vaccines using its proprietary AI-Immunology™ platform, targeting cancer and infectious diseases.
How can investors contact Evaxion?
Investors can contact Mads Kronborg, Vice President of Investor Relations & Communication, directly at +45 53 54 82 96 for inquiries.
